Advertisement
Screener

Acumen Pharmaceuticals, Inc. (ABOS) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Acumen Pharmaceuticals, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Acumen Pharmaceuticals, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $115.54M went out.
  • Fiscal year ended 2025-12-31: from investing, $133.93M came in.
  • Fiscal year ended 2025-12-31: from financing, $34.00K went out.
  • Fiscal year ended 2025-12-31: change in cash, $18.36M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew debtStaff share taxNew shares soldNot split outChange in cash
2025-12-31-$115.54M$133.93M-$73.00K$0.00$18.36M
2024-12-31-$86.22M$48.03M$0.00-$41.00K$7.94M-$969.00K*-$31.26M
2023-12-31-$43.06M-$171.67M$30.00M$0.00$121.90M-$62.98M
2022-12-31-$35.15M$39.19M$0.00$3.79M$7.94M
2021-12-31-$17.96M-$104.12M$168.56M$31.91M*$78.39M
2020-12-31-$7.45M$44.67M*$37.23M

Each quarter (3 month)

Quarter endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$18.07M*$26.00M*$0.00*$27.00K*
2026-03-31-$24.13M-$13.81M-$149.00K$145.00K$35.75M*-$2.19M
2025-12-31-$19.10M*$26.25M*$0.00*$0.00*
2025-09-30-$30.49M*$40.51M*$0.00*$0.00*
2025-06-30-$31.83M*$38.48M*$0.00*$0.00*
2025-03-31-$34.12M$28.69M-$73.00K$37.00K-$5.47M
2024-12-31-$27.21M*$29.66M*-$9.00K*$0.00*
2024-09-30-$24.60M*-$10.13M*$0.00*$0.00*
2024-06-30-$16.55M*$37.70M*$0.00*$0.00*
2024-03-31-$17.86M-$9.20M-$32.00K$7.94M-$799.00K*-$19.95M
2023-12-31-$8.31M*-$48.81M*$0.00*-$390.00K*$29.52M*
2023-09-30-$12.90M*-$92.00M*$0.00*$122.29M*
2023-06-30-$11.67M*$11.06M*$0.00*$0.00*
2023-03-31-$10.18M-$41.93M$0.00$0.00-$52.10M
2022-12-31-$11.20M*-$20.42M*$3.79M*
2022-09-30-$9.18M*$55.92M*$2.00K*
2022-06-30-$6.47M*$8.79M*
2022-03-31-$8.30M-$5.10M-$13.40M
2021-12-31-$3.64M*-$10.01M*-$3.00K*
2021-09-30-$7.69M*-$94.10M*$168.78M*
2021-06-30-$4.26M*
2021-03-31-$2.37M-$2.37M
2020-12-31-$2.86M*
2020-09-30-$1.28M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48